Surrozen, Inc. (NASDAQ:SRZN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Surrozen, Inc. (NASDAQ:SRZN) has been given an average rating of “Moderate Buy” by the five brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $42.00.

A number of equities analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Surrozen from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. HC Wainwright restated a “buy” rating and issued a $44.00 price objective (up from $36.00) on shares of Surrozen in a report on Thursday, May 7th. TD Cowen began coverage on shares of Surrozen in a report on Tuesday, April 21st. They issued a “buy” rating for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 price objective on shares of Surrozen in a report on Tuesday, March 24th.

Insider Buying and Selling at Surrozen

In other news, COO Charles O. Williams sold 2,036 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $67,859.88. Following the completion of the sale, the chief operating officer directly owned 16,571 shares in the company, valued at approximately $552,311.43. The trade was a 10.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the stock in a transaction dated Tuesday, March 24th. The stock was acquired at an average price of $24.69 per share, with a total value of $2,633,386.02. Following the completion of the acquisition, the insider owned 736,554 shares in the company, valued at approximately $18,185,518.26. The trade was a 16.93% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 170,878 shares of company stock valued at $4,232,976 and have sold 8,144 shares valued at $271,440. 31.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Surrozen

Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Surrozen during the 4th quarter valued at $99,000. Citadel Advisors LLC raised its holdings in Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the last quarter. Marshall Wace LLP bought a new stake in Surrozen during the 4th quarter valued at $247,000. Finally, Geode Capital Management LLC raised its holdings in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares during the last quarter. 66.57% of the stock is currently owned by institutional investors.

Surrozen Price Performance

SRZN stock opened at $27.05 on Friday. Surrozen has a one year low of $7.31 and a one year high of $35.00. The stock has a market cap of $314.05 million, a PE ratio of -0.72 and a beta of 0.59. The firm has a 50 day simple moving average of $28.69 and a two-hundred day simple moving average of $23.32.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($11.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($10.56). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 4,810.50%.The company had revenue of $5.00 million during the quarter, compared to analysts’ expectations of $4.00 million. On average, research analysts expect that Surrozen will post -7.2 EPS for the current fiscal year.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.